PCSK9

Overview

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease and member of the proprotein convertase family, primarily expressed in hepatocytes, intestinal cells, and the kidney. Its canonical role in lipid metabolism centers on the post-translational regulation of the low-density lipoprotein receptor (LDLR): after secretion from the liver, PCSK9 binds directly to LDLR on the hepatocyte surface, promoting its lysosomal degradation rather than receptor recycling. The net consequence is a reduction in hepatic LDL uptake, leading to elevated circulating LDL cholesterol (LDL-C) levels. Gain-of-function mutations in PCSK9 cause autosomal dominant hypercholesterolemia, while loss-of-function variants are associated with lifelong low LDL-C and markedly reduced cardiovascular risk, establishing PCSK9 as one of the most validated therapeutic targets in modern preventive cardiology.

Beyond its classical role in cholesterol homeostasis, PCSK9 has emerged as a pleiotropic regulator with functions extending to vascular biology, immune modulation, and oncology. Pharmacological inhibition of PCSK9 — achieved through monoclonal antibodies, small interfering RNA (siRNA), macrocyclic Peptides, and CRISPR-based gene editing — has become a major research and clinical frontier. The protein's involvement in ferroptosis, antigen presentation, and tumor immune evasion, alongside its well-established role in cardiovascular disease, positions PCSK9 at the intersection of multiple therapeutic domains.

Focus of Latest Publications

Recent publications on PCSK9 have focused heavily on therapeutic inhibition and gene editing as strategies to lower LDL cholesterol and reduce cardiovascular risk. Several studies examined established PCSK9-targeting agents, including evolocumab and alirocumab, as well as inclisiran, a small interfering RNA targeting hepatic PCSK9 messenger RNA. These reports included pooled clinical analyses, randomized trials, and trial designs in diverse populations such as Japanese patients, adolescents with heterozygous familial hypercholesterolaemia, patients with recent acute coronary syndrome, people with HIV infection, and patients without known significant atherosclerosis but with diabetes. Across these studies, PCSK9 inhibition was consistently framed as a means to achieve sustained LDL-C lowering, with some trials specifically evaluating broader cardiovascular outcomes and safety.

A second major theme was the development of new modalities for PCSK9 suppression. One publication described enlicitide (MK-0616), an orally active macrocyclic peptide therapeutic against PCSK9, developed through fragment-based synthetic assembly to address issues in an earlier lead compound and selected for clinical progression after improvements in potency, solubility, stability, and pharmacokinetics. Another study reported laroprovstat as the first oral small-molecule PCSK9 inhibitor, presented in the context of a phase 1 trial in treatment-naïve patients with hypercholesterolemia. In parallel, multiple nanotechnology-based delivery systems were engineered for PCSK9 gene editing, including endogenous-metabolite-inspired polyamine-oleic acid lipid nanoparticles and piperazine-derived diamine lipid nanoparticles. These platforms were used to deliver mRNA or CRISPR/Cas9 cargo, achieving on-target editing at the PCSK9 locus in vivo and sustained reductions in circulating PCSK9 and LDL-C in mouse models, with favorable tolerability reported for the optimized formulations.

Beyond lipid metabolism, recent studies linked PCSK9 to additional disease mechanisms. In abdominal aortic aneurysm, PCSK9 was reported to be enriched in vascular smooth muscle cells, where it promoted ferritinophagy-dependent ferroptosis through changes involving FTH1, NCOA4, LC3-II/I, iron accumulation, lipid peroxidation, and GPX4; pharmacological degradation of PCSK9 with the peptide Cadd4 attenuated aneurysm progression in murine models. Another study used Mendelian randomization to suggest that genetically proxied PCSK9 inhibition may be associated with increased odds of diabetic peripheral neuropathy, although observational NHANES analyses did not show a significant association between statin use and diabetic peripheral neuropathy. PCSK9 was also highlighted in oncology-related work, including a rationale for combining alirocumab with anti-PD-1 therapy in immunorefractory metastatic non-small cell lung cancer, based on preclinical evidence that PCSK9 can act as an immunosuppressive regulator of antigen presentation.

Additional publications explored PCSK9 in proteomic and computational contexts. A pilot proteomics study compared plasma profiles in hypercholesterolemic patients with and without familial hypercholesterolemia treated with PCSK9 inhibitors, while another pooled analysis assessed the clinical efficacy of evolocumab in Japanese patients. A transfer-learning framework for peptide-protein interaction prediction identified PCSK9 among candidate cancer-related targets for snake-venom-derived peptides. Together, these studies show that current PCSK9 research spans established lipid-lowering therapy, emerging oral and RNA-based inhibitors, genome-editing approaches, and mechanistic investigations extending into vascular biology, neuropathy, and cancer immunotherapy.

Key Publications

• NEWJul Endogenous-metabolite-inspired polyamine-oleic acid lipids for safe mRNA delivery and PCSK9 gene editing. (Journal of controlled release : official journal of the Controlled Release Society, 2026, PMID 42401241): "Moreover, Agm-oa LNPs-mediated adenine base editor delivery achieved efficient on-target editing at the PCSK9 locus."
• NEWJul Lower Risk of Type 2 Diabetes Mellitus With PCSK9 Inhibitors Compared With Other Lipid-Lowering Agents Among Patients With Hyperlipidaemia. (Diabetes/metabolism research and reviews, 2026, PMID 42274293): "The purpose of this paper is to compare the risk of incident type 2 diabetes mellitus (T2DM) among patients with hyperlipidaemia treated with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors versus statins and other nonstatin lipid-lowering agents."
• NEWJun Targeting PCSK9 in Vascular Smooth Muscle Cells: An Effective Strategy to Suppress Ferroptosis and Attenuate Abdominal Aortic Aneurysm Progression. (Cell proliferation, 2026, PMID 42269711): "This study examines whether proprotein convertase subtilisin/kexin type 9 (PCSK9) drives ferroptosis in vascular smooth muscle cells (VSMCs) and whether its pharmacological degradation mitigates disease progression."
• Jun Discovery Process of Enlicitide, a Highly Engineered Macrocyclic Peptide Therapeutic, through Issue-Driven Fragment-Based Synthetic Assembly and SAR. (Journal of medicinal chemistry, 2026, PMID 42201324): "Herein, we report the discovery process of enlicitide (MK-0616, compound 18), an orally active macrocyclic peptide therapeutic against PCSK9 for LDL-C reduction."
• May Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients. (Circulation, 2026, PMID 42137960): "Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) is an effective therapy for reducing low-density lipoprotein (LDL) cholesterol (LDL-C) in adults with hyperlipidemia, including heterozygous familial hypercholesterolemia, thereby lowering cardiovascular risk."
• May Low-Density Lipoprotein Cholesterol Lowering With Inclisiran Plus Usual Care in Recent Acute Coronary Syndrome: VICTORION-INCEPTION, a Randomized, Controlled, Open-Label Trial. (Journal of the American Heart Association, 2026, PMID 42132192): "The low-density lipoprotein cholesterol (LDL-C)-lowering effect of inclisiran, a proprotein convertase subtilisin/kexin type 9-targeting small interfering RNA, has not been established in patients with recent acute coronary syndrome."
• May Piperazine-Derived Diamine Lipid Nanoparticles Targeting to the Liver for Delivering Clustered Regularly Interspaced Short Palindromic Repeat Editing of PCSK9 to Durably Maintain Plasmatic Low-Density Lipoprotein Cholesterol in Low Levels. (ACS applied bio materials, 2026, PMID 42080223): "A single intravenous dose mediates robust PCSK9 gene editing in C57BL/6 mice, resulting in sustained reductions of circulating PCSK9 and LDL-C levels under both normal and high-fat diet conditions for up to 48 days, accompanied by decreased hepatic PCSK9 expression."
• May Statin Use and Neuropathic Pain: Evidence from NHANES and Mendelian Randomization Analyses. (Molecular neurobiology, 2026, PMID 42081017): "evaluate whether genetically proxied inhibition of HMGCR, PCSK9, and NPC1L1 is associated with DPN, trigeminal neuralgia (TN), and postherpetic neuralgia (PHN)."
• Apr Clinical Efficacy with Evolocumab among Japanese Patients in PROFICIO: A Pooled Analysis of 1,040 Patients. (Journal of atherosclerosis and thrombosis, 2026, PMID 41987365): "This study assessed the clinical efficacy of evolocumab, a human monoclonal antibody targeting PCSK9, in Japanese patients using data from the PROFICIO program."
• Apr Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study. (Future oncology (London, England), 2026, PMID 41940540): "Preclinical studies have identified PCSK9 as an immunosuppressive regulator of antigen presentation, providing a compelling rationale for therapeutic PCSK9 inhibition as a strategy to overcome resistance to immune checkpoint blockade."